GSK3787

CAS No. 188591-46-0

GSK3787( GSK3787 | GSK-3787 | GSK 3787 )

Catalog No. M12948 CAS No. 188591-46-0

GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
5MG 48 In Stock
10MG 75 In Stock
25MG 174 In Stock
50MG 302 In Stock
100MG 510 In Stock
200MG Get Quote In Stock
500MG 1088 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK3787
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
  • Description
    GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
  • In Vitro
    GSK3787 is identified as a potent and selective hPPARδ ligand (pIC50=6.6) with no measurable affinity for hPPARα or hPPARγ (pIC50 < 5) in our standard in vitro ligand displacement assay. GSK3787 is inactive against hPPARα and hPPARγ in similar functional antagonist assays. GSK3787 fails to activate the receptor in a standard hPPARδ-GAL4 chimera cell-based reporter assay. GSK3787 is a selective PPARδ antagonist with equipotent species activity against the human and mouse receptor.
  • In Vivo
    GSK3787 has pharmacokinetic properties suitable for use as an in vivo PPARδ antagonist tool compound in mice. GSK3787 is administered intravenously (0.5 mg/kg) and orally (10 mg/kg) to male C57BL/6 mice. Mean clearance (CL) and volume of distribution at steady state (Vss) following iv administration are 39±11 (mL/min)/kg and 1.7±0.4 L/kg, respectively. Following oral administration, good exposure (Cmax=881±166 ng/mL, AUCinf=3343±332 h?ng/mL), half-life (2.7±1.1 h), and bioavailability (F=77±17%) are observed. Oral administration of GSK3787 (10 mg/kg) leads to a serum Cmax of 2.2±0.4 μM in C57BL/6 male mice. Oral administration of GW0742 causes an increase in expression of Angptl4 and Adrp mRNA (known PPARβ/δ target genes) in wild-type mouse colon epithelium, and this effect is not found in Pparβ/δ-null mouse colon epithelium. Coadministration of GSK3787 with GW0742 effectively prevents the ligand-induced expression of both Angptl4 and Adrp mRNA in wild-type mouse colon epithelium, and this effect is not found in Pparβ/δ-null mouse colon epithelium. Oral administration of GSK3787 causes a modest increase in promoter occupancy of PPARβ/δ in the PPRE region of both the Angptl4 and Adrp genes, but coadministration of GSK3787 with GW0742 results in markedly less accumulation of PPARβ/δ in the PPRE region of both the Angptl4 and Adrp genes in wild-type mouse colon epithelium.
  • Synonyms
    GSK3787 | GSK-3787 | GSK 3787
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPARδ
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    188591-46-0
  • Formula Weight
    392.78
  • Molecular Formula
    C15H12ClF3N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 79 mg/mL (201.13 mM)
  • SMILES
    O=C(NCCS(=O)(C1=NC=C(C(F)(F)F)C=C1)=O)C2=CC=C(Cl)C=C2
  • Chemical Name
    4-chloro-N-(2-((5-(trifluoromethyl)pyridin-2-yl)sulfonyl)ethyl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Shearer BG, et al. J Med Chem, 2010, 53(4), 1857-186
molnova catalog
related products
  • Seladelpar

    A potent, selective, orally bioavailable PPARδ agonist for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

  • Pemafibrate

    A highly potent, specific PPARα agonist with EC50 of 1 nM.

  • GW 9662

    GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM in a cell-free assay.